INCY - Incyte Corporation

https://www.incyte.com

Buy Momentum: Bearish

Recent News

Incyte ( INCY ) Up 9.4% Since Last Earnings Report: Can It Continue?

Zacks Commentary • 2 weeks, 4 days ago • score: 0.20

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bullish

INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?

Zacks Commentary • 3 weeks, 5 days ago • score: 0.44

Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Uptrend

As of 2025-09-10 (Snapshot)

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.

52W High

$87.99

52W Low

$53.56

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.75

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

20.48

Forward P/E (<15 better)

12.56

EV/EBITDA (<8 favorable)

10.73

EV/Revenue (<3 favorable)

3.17

P/S (TTM) (<3 favorable)

3.69

P/B (<3 favorable)

4.06

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

2.03%

Institutions (25–75% balanced)

103.45%

Shares Outstanding

195,276,000

Float

163,042,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

4,584,996,000

Gross Profit (TTM)

2,440,260,000

EPS (TTM)

4.23

Profit Margin (>10% good)

0.19%

Operating Margin (TTM) (higher better)

0.26%

ROE (TTM) (>15% strong)

0.24%

EPS YoY (Quarterly) (>10% good)

0.07

Revenue YoY (Quarterly) (>8% good)

0.17

Momentum

Bearish momentum

Value

1.9075

2.3742

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025